Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 5—May 2014
Research

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Suzanne M. MarksComments to Author , Jennifer Flood, Barbara Seaworth, Yael Hirsch-Moverman, Lori Armstrong, Sundari Mase, Katya Salcedo, Peter Oh, Edward A. Graviss, Paul W. Colson, Lisa Armitige, Manuel Revuelta, Kathryn Sheeran, and the TB Epidemiologic Studies Consortium
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Marks, L. Armstrong, S. Mase, TB Epidemiologic Studies Consortium); California Department of Public Health, Richmond, California, USA (J. Flood, K. Salcedo, P. Oh); Texas Department of State Health Services, Tyler, Texas, USA (B. Seaworth, L. Armitige, K. Sheeran); University of Texas Health Science Center, Tyler (B. Seaworth, L. Armitige, K. Sheeran); ICAP/Columbia University, New York, New York, USA (Y. Hirsch-Moverman, P.W. Colson, M. Revuelta); Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss)

Main Article

Table 6

Treatment outcomes of MDR/XDR TB study patients alive at diagnosis, by resistance pattern, California, Texas, and New York City, USA, 2005–2007*

Resistance pattern Completed treatment, % Transferred within United States, % Transferred out of United States, % Lost to follow-up, % Stopped because of side effects, % Died during treatment, %
All, N = 134 78 3 6 2 1 9
INH/RIF/RBT-only, n = 17 59 0 18 6 0 18
INH/RIF/RBT-plus, n = 58 83 3 7 0 0 7
First-line, n = 32 78 0 3 6 3 9
Pre-XDR, n = 22 77 9 0 0 5 9
XDR, n = 5
 100
 0
 0
 0
 0
 0
*MDR TB, multidrug-resistant tuberculosis; XDR TB, extensively drug-resistant TB; INH, isoniazid; RIF, rifampin; RBT, rifabutin.

Main Article

Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external